RecruitingNot ApplicableNCT06506942
The TRICURE EFS Study
The TRICURE EFS TRiCares Topaz Transfemoral TRICUspid Heart Valve REplacement System Early Feasibility Study
Sponsor
TRiCares
Enrollment
15 participants
Start Date
Sep 11, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Adult patients
- Tricuspid regurgitation grade 3 (severe) on a scale of 0 (none) to 5 (torrential)
- Institutional Heart Team evaluates patient as being at increased operative risk
Exclusion Criteria4
- Patient in need of emergent intervention
- Patient who is hemodynamically unstable
- Anatomical contraindications for implantation with study device
- Patient who is currently participating in another clinical investigation where the primary endpoint was not reached yet
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICETranscatheter Tricuspid Valve Replacement
Replacement of the tricuspid valve through a transcatheter approach
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06506942
Related Trials
American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)
NCT041858443 locations
Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health
NCT069532321 location
Clinical Study of the inQB8 TTVR System (The MonarQ Study)
NCT066115798 locations
Green Propolis Extract and Royal Jelly in Hypertensive Patients and/or With Chronic Kidney Disease
NCT062882042 locations
Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
NCT074493252 locations